Clinical Report: Patterns of Medication Initiation, Discontinuation, and Adherence in ADHD
Overview
This study characterizes medication initiation, discontinuation, and adherence patterns among Norwegian youth diagnosed with ADHD. Findings indicate significant discontinuation rates, particularly among older adolescents and females, highlighting the need for targeted clinical monitoring.
Background
ADHD is a prevalent neurodevelopmental disorder that affects functioning across various life domains. Effective long-term management of ADHD is heavily reliant on medication adherence, yet many patients, especially adolescents, struggle with persistence in treatment. Understanding the patterns of medication use is crucial for improving outcomes and addressing the barriers to adherence.
Data Highlights
Measure
Findings
Medication Initiation
74.3% initiated medication
Median Time to Initiation
106 days (IQR 17–231)
Discontinuation in Adolescents (15-17 years)
31.9 fewer days on treatment compared to children (5-11 years)
Discontinuation by Sex
Females discontinued 13.2 days earlier than males
Key Findings
74.3% of the cohort initiated ADHD medication.
55% of individuals initiated medication within 90 days of diagnosis.
Discontinuation rates increased significantly with age, particularly in adolescents aged 15-17 years.
Females discontinued medication earlier than males, with a significant difference of 13.2 days.
Longitudinal analysis showed older age at initiation and female sex correlated with a steeper decline in medication adherence over time.
Clinical Implications
The findings suggest that clinicians should closely monitor older adolescents and females for medication adherence and potential discontinuation. Structured transition planning and addressing sex-specific barriers may be beneficial in supporting treatment continuity.
Conclusion
Discontinuation and low adherence to ADHD medication are prevalent issues that escalate during adolescence, particularly among females. Targeted interventions may be necessary to improve adherence in these high-risk groups.
Online interest in leucovorin, folate products, and acetaminophen-related autism concerns increased markedly in the 2 weeks following the White House announcement.
